Search: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma

Journal of Clinical Oncology

Volumn 33, Issue 6, 2015, Pages 559-566

  Zhu, Andrew X ^a   Rosmorduc, Olivier ^b   Evans, T R Jeffry ^d   Ross, Paul J ^e   Santoro, Armando ^f   Carrilho, Flair Jose ^g   Bruix, Jordi ^h   Qin, Shukui ^j   Thuluvath, Paul J ^k   Llovet, Josep M ^h,i,l   Leberre, Marie Aude ^c   Jensen, Markus ^m   Meinhardt, Gerold ⁿ   Kang, Yoon Koo ^o  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e KING S COLLEGE HOSPITAL   (United Kingdom)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^j University of People's Liberation Army   (China)

^k MERCY MEDICAL CENTER   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m BAYER AG   (Germany)

ⁿ BAYER CORPORATION   (United States)

^o University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PLACEBO; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CHILD PUGH SCORE; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; INTERSTITIAL LUNG DISEASE; KERATITIS; LIVER CELL CARCINOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PLACEBOS; QUINAZOLINES;

EID: 84923144891     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.7746     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Thomas MB, Jaffe D, Choti MM, et al: Hepatocellular carcinoma: Consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994-4005, 2010
3. National Comprehensive Cancer Network: NCCN Guidelines Version 2.2013, 2013. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
4. Bayer HealthCare Pharmaceuticals: Nexavar (tablets, oral): Prescribing information. Wayne, NJ, Bayer HealthCare Pharmaceuticals, 2012
5. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004
6. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
7. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009
8. Tazi el M, Essadi I, M'rabti H, et al: Systemic treatment and targeted therapy in patients with advanced hepatocellular carcinoma. N Am J Med Sci 3:167-175, 2011
9. Zhu AX: Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: Current status and future perspectives. Semin Oncol 39:493-502, 2012
10. Berasain C, Nicou A, Garcia-Irigoyen O, et al: Epidermal growth factor receptor signaling in hepatocellular carcinoma: Inflammatory activation and a new intracellular regulatory mechanism. Dig Dis 30:524-531, 2012
11. Bassullu N, Turkmen I, Dayangac M, et al: The predictive and prognostic significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 expression in hepatocellular carcinoma. Hepat Mon 12: e7492, 2012
12. Ezzoukhry Z, Louandre C, Trécherel E, et al: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 131:2961-2969, 2012
13. Blivet-Van Eggelpoël MJ, Chettouh H, Fartoux L, et al: Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 57:108-115, 2012
14. Iyer R, Bharthuar A: A review of erlotinib-An oral, selective epidermal growth factor receptor tyrosine kinase inhibitor. Expert Opin Pharmacother 11:311-320, 2010
15. Steins M, Thomas M, Geissler M: Erlotinib. Recent Results Cancer Res 184:21-31, 2010
16. Astellas Pharma US, Genentech: Tarceva (erlotinib tablets, oral): Prescribing information. Farmingdale, NY, Astellas Pharma US, Genentech, 2012
17. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657-6663, 2005
18. Thomas MB, Chadha R, Glover K, et al: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1067, 2007
19. Duran I, Hotté SJ, Hirte H, et al: Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13:4849-4857, 2007
20. Lencioni R, Llovet JM, Han G, et al: Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): Phase II, randomized, double-blind SPACE trial. J Clin Oncol 30, 2012 (suppl; abstr LBA154)
21. Kudo M, Imanaka K, Chida N, et al: Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47:2117-2127, 2011
22. Hughes AN, O'Brien ME, Petty WJ, et al: Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220-1226, 2009
23. Waller LL, Miller AA, Petty WJ: Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke. Lung Cancer 67:12-16, 2010
24. Pitarch G, Garde J, Torrijos A, et al: Adverse cutaneous reactions to erlotinib. Actas Dermosifiliogr 99:54-60, 2008
25. Lacouture ME, Wu S, Robert C, et al: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-1011, 2008
26. Cheng AL, Kang YK, Lin DY, et al: Sunitinib versus sorafenib in advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 31:4067-4075, 2013
27. Cainap C, Qin S, Huang WT, et al: Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 31, 2013 (suppl 4; abstr 249)
28. Johnson PJ, Qin S, Park JW, et al: Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: Results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517-3524, 2013
29. Llovet JM, Decaens T, Raoul JL, et al: Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: Results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509-3516, 2013
30. Llovet JM, Di Bisceglie AM, Bruix J, et al: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008